Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Organogenesis Holdings (ORGO) over the last 8 years, with Q3 2025 value amounting to $2.2 million.

  • Organogenesis Holdings' Capital Expenditures fell 1300.12% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 2866.43%. This contributed to the annual value of $10.0 million for FY2024, which is 5882.45% down from last year.
  • Organogenesis Holdings' Capital Expenditures amounted to $2.2 million in Q3 2025, which was down 1300.12% from $3.6 million recorded in Q2 2025.
  • Organogenesis Holdings' Capital Expenditures' 5-year high stood at $16.7 million during Q3 2021, with a 5-year trough of $1.9 million in Q2 2024.
  • For the 5-year period, Organogenesis Holdings' Capital Expenditures averaged around $5.7 million, with its median value being $5.0 million (2021).
  • In the last 5 years, Organogenesis Holdings' Capital Expenditures skyrocketed by 18557.02% in 2021 and then tumbled by 7493.0% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Capital Expenditures (Quarter) stood at $5.2 million in 2021, then soared by 103.86% to $10.7 million in 2022, then plummeted by 68.81% to $3.3 million in 2023, then increased by 1.11% to $3.4 million in 2024, then plummeted by 33.5% to $2.2 million in 2025.
  • Its Capital Expenditures stands at $2.2 million for Q3 2025, versus $3.6 million for Q2 2025 and $3.6 million for Q1 2025.